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Summary
Background Antimicrobial resistance is highly prevalent in low-income and middle-income countries. International 
travel contributes substantially to the global spread of intestinal multidrug-resistant Gram-negative bacteria. 
Hundreds of millions of annual visitors to low-income and middle-income countries are all exposed to intestinal 
multidrug-resistant Gram-negative bacteria resulting in 30–70% of them being colonised at their return. The 
colonisation process in high-exposure environments is poorly documented because data have only been derived from 
before travel and after travel sampling. We characterised colonisation dynamics by exploring daily stool samples while 
visiting a low-income and middle-income countries.
Methods In this prospective, daily, real-time sampling study 20 European visitors to Laos volunteered to provide daily 
stool samples and completed daily questionnaires for 22 days. Samples were initially assessed at Mahosot Hospital, 
Vientiane, Laos, for acquisition of extended-spectrum β-lactamase-producing (ESBL) Gram-negative bacteria followed 
by whole-genome sequencing of isolates at MicrobesNG, University of Birmingham, Birmingham, UK. The primary 
outcome of the study was to obtain data on the dynamics of intestinal multidrug-resistant bacteria acquisition.
Findings Between Sept 18 and Sept 20, 2015, 23 volunteers were recruited, of whom 20 (87%) European volunteers 
were included in the final study population. Although colonisation rates were 70% at the end of the study, daily 
sampling revealed that all participants had acquired ESBL-producing Gram-negative bacteria at some point during 
the study period; the colonisation status varied day by day. Whole-genome sequencing analysis ascribed the transient 
pattern of colonisation to sequential acquisition of new strains, resulting in a loss of detectable colonisation by the 
initial multidrug-resistant Gram-negative strains. 19 (95%) participants acquired two to seven strains. Of the 83 unique 
strains identified (53 Escherichia coli, 10 Klebsiella spp, and 20 other ESBL-producing Gram-negative bacteria), some 
were shared by as many as four (20%) participants.
Interpretation To our knowledge, this is the first study to characterise in real-time the dynamics of acquiring 
multidrug-resistant Gram-negative bacterial colonisation during travel. Our data show multiple transient colonisation 
events indicative of constant microbial competition and suggest that travellers are exposed to a greater burden of 
multidrug-resistant bacteria than previously thought. The data emphasise the need for preventing travellers’ diarrhoea 
and limiting antibiotic use, addressing the two major factors predisposing colonisation.
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Trust, Medical Research Council; The Royal Society; Joint Programming Initiative on Antimicrobial Resistance, and 
European Research Council.
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Introduction
Antimicrobial resistance poses a serious threat 
to human health worldwide.1 The rapid global spread 
of multidrug-resistant clones of Escherichia coli, 
Klebsiella pneumoniae, and other Enterobacteriaceae 
raises an alarming public health concern.1 Worldwide 
dissemination of successful clones, such as E coli 
sequence type (ST)131, has been the primary driver 
of the increased prevalence of extended-spectrum 
β-lactamase (ESBL)-producing E coli in clinical isolates.2 
Correspondingly, the global spread of carbape nemase-
producing clones of E coli, such as ST4103 and ST167,4 
and K pneumoniae clones, such as CG258 and ST11,5 
largely account for the rapid emergence of carbapenem 
resistance in clinical isolates of Gram-negative patho-
gens worldwide.
The literature suggests international travel is strongly 
associated with the acquisition of multidrug-resistant 
Gram-negative strains; ESBL-producing E coli bacteria are 
the most common, with 30–70% of travellers colonised.6–11 
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The carriage rate of intestinal multidrug-resistant Gram-
negative bacteria is highest in people from the south and 
southeast Asia, followed by Africa and South America. 
People visiting these high-risk regions are at substantial 
risk of acquiring multidrug-resistant Gram-negative 
bacteria.11 Colonisation occurs even during short visits 
(1–5 days),6–11 can last for months or even over a year 
without antimicrobial use,6,8,9,12 and can lead to further 
spread after return home.6,9 Genome-level analysis of 
multidrug-resistant strains colonising travellers suggests 
that newly acquired multidrug-resistant strains tend to 
displace resident intestinal commensal E coli strains 
alongside new non-multidrug-resistant strains, so that the 
pretravel population remains but as a minority.13
In previous studies of travellers’ intestinal colonisation 
by multidrug-resistant Gram-negative bacteria, samples 
have been taken immediately before travel and upon 
return home.6–10 As such, the dynamics of this com-
petitive colonisation process are unknown. Here we 
present a longitudinal study done in Laos; the aim of the 
study was to characterise the colonisation dynamics 
using fine-scale genomic analysis of daily stool samples 
from volunteers.
Methods
Study design and participants
To obtain data on the dynamics of intestinal multidrug-
resistant bacteria acquisition, we characterised the 
colonisation process by ESBL-producing Gram-negative 
bacteria by sampling participants’ stools on arrival in 
Vientiane, Laos, each day abroad, and at departure. The 
study was done over 22 days.
Volunteers were recruited prospectively from partici-
pants at a medical course held from Sept 19 to Oct 9, 2015, 
in Vientiane. We also invited the recruitees’ companions 
to volunteer. Each participant was asked to provide daily 
stool samples while staying in Vientiane. Those collected 
within the first 2 days were considered as baseline 
samples and the final stool sample was considered 
the departure samples. Questionnaires assessing 
background information and travel-related data were 
used at recruitment and before departure. During the 
stay, the volunteers were asked to complete a health card 
to record gastrointestinal symptoms, food habits, 
and medication use each day. Travellers’ diarrhoea was 
defined as passage of three or more loose or liquid stools 
per day. Any ESBL-producing Gram-negative bacteria not 
Research in context
Evidence before this study
We searched PubMed using the terms “beta-lactamase [MeSH]”, 
and “travel” from the inception of the database to Dec 31, 2019, 
for human studies in any language. Over the past decade, 
several investigations reported a high incidence of travel-
associated colonisation by extended-spectrum β-lactamase 
(ESBL)-producing Enterobacteriaceae for travellers returning 
from tropical and subtropical countries. Apart from destination, 
travellers’ diarrhoea and antibiotic use abroad were identified as 
major factors predisposing to colonisation. So far, studies 
exploring travel-acquired ESBL- producing Enterobacteriaceae 
have focused on findings in post-travel stool. Only one of the 
investigations reviewed covered the initial stages of acquisition, 
analysing colonisation dynamics over time, but this study did 
not use real-time analyses or whole-genome sequencing.
Added value of this study
To our knowledge, this is the first report characterising in 
real-time the dynamics of ESBL-producing Enterobacteriaceae 
colonisation during travel to low-income and middle-income 
countries, with daily stool specimens immediately analysed in a 
modern microbiology laboratory (Wellcome Trust) on location. 
Sampling solely after travel would have yielded a multidrug-
resistant Gram-negative colonisation rate of 70%, but daily 
specimen collection revealed a 100% colonisation rate. 
The acquisition was found to be transient in nature, with 
detectable colonisation generally lasting one or a few days at 
most. By analysing isolates from selective primary stool cultures 
by whole-genome sequencing, the number of individual strains 
contracted was found to be much higher than anticipated. 
19 of 20 participants acquired several different ESBL-producing 
Enterobacteriaceae strains (2–7 per participant), with a total of 
83 individual strains. Our data show that the numerous studies 
of travellers’ colonisation rates have, to date, underestimated 
the burden. When sampling only before and after travel, the 
actual burden of multidrug-resistant bacteria is much smaller 
than it really is because many episodes of multidrug-resistant 
Gram-negative acquisition lead to transient colonisation were 
no longer verifiable after travel. Revealing this transient pattern 
of colonisation where sequential acquisitions of new strains far 
exceed the figures previously reported, our data considerably 
widen the current understanding of multidrug-resistant 
acquisition abroad.
Implications of all the evidence available
Our novel observation of multiple transient multidrug-resistant 
acquisitions in visitors to low-income and middle-income 
countries unravels the dynamics of the colonisation event. 
Its transient nature implies a competition between resistant 
strains and an individual’s own microbiota, as suggested by the 
generally rapid disappearance of the bacteria soon after return 
to a high-income country. Besides revealing the antimicrobial 
resistance burden abroad, the surprisingly high number of 
multidrug-resistant strains acquired might indicate a greater 
risk for travellers than previously thought because each of these 
strains might have the potential to transfer resistance genes to 
members of the individuals’ microbiota. Mechanisms 
underlying the competition between clones should be 
scrutinised in more detail and methods fight off colonisation 
already at initial stages must be identified.
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found in the baseline samples but detected in one or 
more stool samples taken later were defined as travel-
acquired ESBL-producing Gram-negative bacteria. Only 
volunteers providing at least five daily samples over the 
22-day period were included in the final cohort. The 
study protocol (appendix 1) was approved by the Ethics 
Committee of the Helsinki University Hospital, Helsinki, 
Finland, and the Ethics Committee of Northwest and 
Central Switzerland, Basel, Switzerland. All participants 
provided written informed consent.
Procedures
The initial screening for presumptive ESBL-producing 
Gram-negative bacteria strains from stool samples was 
done at the Microbiology Laboratory of Mahosot Hospital, 
Vientiane, Laos by culture on CHROMagar ESBL 
agar plates (CHROMagar, Paris, France). Phenotypically 
distinct colonies were subcultured and stored at –80°C in 
Protect tubes (Technical Service Consultants, Heywood, 
UK) with the original swabs. The samples were then 
transported by plane on dry ice first to the Swiss Tropical 
and Public Health Institute, Basel, Switzerland, and then 
to the University of Helsinki, Helsinki, Finland, for 
analyses. In Finland, the bacteria were recultured on an 
equivalent chromogenic media, ChromID ESBL agar 
(BioMérieux, Marcy-l’Étoile, France), and a colony of all 
morphotypes present on the ChromID plate was sub-
cultured and cryopreserved. The isolates were shipped 
on dry ice to the University of Birmingham, Birmingham, 
UK, for genome sequencing by the MicrobesNG facility. 
Libraries were prepared using the Nextera XT kit 
(Illumina, San Diego, CA, USA) and sequenced on the 
Illumina HiSeq platform (Illumina).
Illumina genome sequence reads were assessed for 
quality using FastQC (version 0.11.9) and subsequently 
trimmed using Trimmomatic (version 0.3),14 with a 
sliding window quality of Q15 and length of 20 base 
pairs. Kraken (version 2) was used to speciate isolates 
against all bacterial, archaeal, and viral genomes within 
the RefSeq database up to Nov 1, 2017. De novo assembled 
genomes were produced using SPAdes (version 3.13.0) 
under default conditions, with the inclusion of the 
careful flag.15 Assemblies were also built using SKESA 
(version 2.3.0) under default conditions. Resulting 
assembled genomes were annotated using Prokka 
(version 1.11) under default conditions.16
Antibiotic resistance genes were detected in assembled 
and annotated genomes using Abricate (version 0.8.7) and 
the ResFinder database. Abricate detected all genes with a 
minimum identity of 75% and a minimum coverage of 
0%. Partial hits to genes were then manually assessed 
because of the occasional splitting of genes (particularly 
on plasmids). Genes that were present in the total 
assembly at a coverage of 90% were determined to be 
present. Prokka-annotated genomes were manually 
inspected to confirm the presence of resistance genes 
identified. MLST (version 2.15) was used to verify species 
identification and assign classical ST designations to 
isolates. Phylogroups were assigned using ClermonTyping.
Isolates were examined for potential relationships by 
criteria including participant number, ST, resistance 
profile, and phylogenetic distribution. Where isolates were 
suspected of sharing recent source or transmission events, 
Snippy (version 4.3.6) was used to map reads of isolates 
against the assembled genome of the earliest relative 
isolate. The assemblies of all isolates within identified 
clusters were highly similar (appendix 2 p 7). The number 
of single nucleotide polymorphisms between strains was 
determined using snp-dists (version 0.6.3).
Phylogenies were reconstructed using RaxML-NG under 
the GTR-GAMMA model (version 0.6.0), a core single 
nucleotide polymorphism alignment from Snippy-core 
(version 4.3.6). Phylogenies were midpoint rooted and 
combined with metadata for visualisation in Phandango 
(version 1.3.0). E coli isolates were screened for virulence 
factors using the ecoli_vf and vfdb databases bundled in the 
base version of Abricate. These isolates were then assigned 
to pathotypes using a previously described scheme17
Outcomes
The primary outcome of the study is real-time data on 
the dynamics of intestinal multidrug-resistant bacteria 
acquisition while visiting low-income and middle-
income countries
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of this Article.
See Online for appendix 1
See Online for appendix 2
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Results
Between Sept 18 and Sept 20, 2015, a total of 23 volunteers 
were recruited (appendix 2 p 2), three of whom were 
excluded because they only provided two samples (of note, 
ESBL Gram-negative bacteria was found in all six 
samples). 20 (87%) European volunteers were included in 
the final study population (figure 1). Of the volunteers, 
ten (50%) were younger than 50 years, 11 (55%) were 
women, and 19 (95%) were medical doctors. The median 
age was 42·5 years (IQR 33·5−57·0), and the median 
duration of stay in Laos was 20 days (IQR 12−21). 
Five (25%) parti cipants had used antimicrobial medication 
during the previous year, three (15%) arrived directly from 
another tropical region, one (5%) had visited the tropics 
within the past 3 months, and seven (35%) had visited the 
tropics within the last year (appendix 2 p 2). The group 
provided a total of 236 stool samples.
During the sampling period, the volunteers stayed at 
three separate hotels, visited various restaurants either 
in small groups or all together, and participated in daily 
rounds at local hospitals. Four (20%) participants 
reported travellers’ diarrhoea and one (5%) took anti-
biotics (appendix 2 p 2).
ESBL-producing Gram-negative bacteria strains 
were detected in the primary samples of seven (35%) 
participants, including three who had arrived in Laos 
directly from another Asian country. For all participants 
at least one stool specimen tested positive for ESBL-
producing Gram-negative bacteria in culture by day 10 of 
their visit (figure 2). Of the 236 faecal samples collected, 
174 (74%) contained detectable ESBL-producing Gram-
negative bacteria, yielding a total of 306 isolates. Of these, 
292 (95%) isolates were successfully whole-genome 
sequenced. E coli was the most abundant species isolated, 
accounting for 219 (75%) of the 292 isolates. The other 
species identified were Citrobacter spp (28 [10%] isolates), 
Klebsiella spp (16 [5%] isolates), Acinetobacter spp 
(12 [4%] isolates), and Enterobacter cloacae (11 [4%] 
isolates); a number of other low-prevalence species, 
including Aeromonas spp and Stenotrophomonas 
maltophilia were also present (appendix 2 pp 18−28). 
When allocating individual isolates to the participants, 
colonisation by any given ESBL-producing Gram-
negative bacteria during the study was clearly transient 
in nature: isolates were detected in only one or a few 
samples obtained from any given individual, sometimes 
with days between isolation.
The genomes of all 292 isolates were found to contain 
at least one antimicrobial resistance gene. The most 
prevalent ESBL gene type was blaCTX-M found in a total of 
226 (77%) isolates, with CTX-M-55 (64 [28%]), CTX-M-14 
(58 [26%]), CTX-M-159 (57 [25%]), CTX-M-15 (30 [13%]), 
and CTX-M-102 (25 [11%]) the most common types 
(appendix 2 p 6). Some isolates contained multiple CTX-M 
types. Mobile colistin resistance genes were found in 
82 isolates (28%), all but two of which were E coli 
(one Aeromonas sp and one other K pneumoniae). 
Superimposing MLST (multilocus sequence typing) desig-
nation (figure 2; appendix 2 p 4) and bla/mobile colistin 
resistance gene type (figure 3) onto each participants 
isolates provided further insight into the transient nature of 
gut colonisation (figure 3). Although one (5%) participant 
was found to have contracted a single ST2067 strain of 
E coli carrying CTX-M-15, the other 19 (95%) participants 
were colonised by multiple E coli STs and co-colonised by 
other ESBL-producing Gram-negative bacteria species. For 
example, one parti cipant took azithromycin for travellers’ 
diarrhoea from Sept 21 to 23, 2015, and was transiently 
colonised by five different E coli strains during the study, 
each with different bla gene repertoires. Participant 16 had 
a regular flux between isolation of an ST38, ST93, and 
ST101 strain, whereas participant 40 had initial colonisation 
Figure 2: Colonisation of participants by ESBL-producing Gram-negative 
bacteria
Strains are shown by participant, with a maximum of five differing strains 
identified from the samples of a single individual. Because of the large number 
of constituent strains in the database, the colour designations do not represent 
the same strains across multiple volunteers. Days where no symbol is present 
indicates that a participant was unable to produce a sample. ESBL=extended-
spectrum β-lactamase. *Dashed lines represent maintenance of a single strain 
over multiple days interrupted by colonisation by another strain of the same 
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by an ST48 strain, which was later displaced by an ST38 
strain. All these strains have unique signatures of carriage 
of multiple bla genes, suggesting that travellers are exposed 
to a large number of multidrug-resistant Gram-negative 
bacteria and multidrug-resis tance conferring genes 
during the initial colonisation process (figure 3). 19 (95%) 
participants acquired between two and seven strains. All 
the strains were identified as extraintestinal pathogenic 
E coli, with the exception of a small number of strains 
(seven [3%] of 219 E coli isolates) containing a Virulence 
associated gene profile and ST designation consistent with 
multidrug-resistant atypical enteropathogenic E coli strains 
(appendix 2 pp 9−17).
We analysed the population of E coli isolates at MLST 
designation level (figure 4). The most common E coli STs 
identified were ST101, ST34, ST38, and ST195. These 
lineages are very uncommon in surveys of ESBL resistant 
and carbapenem resistant E coli, both in isolates from 
Europe and previous human isolates from Laos.18,19 
Superimposing the presence of specific ESBL-producing 
E coli and mobile colistin resistance genes onto a 
phylogenetic tree of the E coli isolates revealed blaCTX-M genes 
to be ubiquitous throughout the sampled popu lation, with 
mobile colistin resistance genes also widely distributed 
across the population (appendix 2 p 5). Analysis of the 
K pneumoniae lineages showed isolates belonging 
predominantly to ST2176 and ST37, neither of which are 
well characterised, globally disseminated clones.20
When analysing the population structure of the E coli 
isolates, very little diversity was found in strains within 
each of the different lineages. To investigate relationships 
between isolates within the lineages, a high-resolution 
single nucleotide polymorphism analysis using the first 
isolated strain as a reference was done. Our data showed 
common strains colonising participants, often with no 
single nucleotide polymorphisms difference between 
them (figure 5). An identical ST515 strain colonised 
participants 6, 17, 33, and 5, and an identical ST38 
colonised participants 5, 40, and 13. Participants 19 and 
34 shared an identical ST34 strain, and participants 6 and 
Figure 3: Resistance determinants identified in ESBL-producing Gram-negative 
bacteria isolates

































































































Figure 4: Abundance of unique STs in the stool samples of volunteers
Isolates were examined using a high-resolution single nucleotide polymorphism analysis. Isolates belonging to the 













































































































Figure 5: Linkage of isolates between participants
High resolution SNP analysis identified several instances of a single strain 
colonising multiple participants. Most strains did not contain any variation. 5 of 
the 33 isolates contained between 1-5 SNPs. The most prolifically shared strain 
(ST-515) found in participants 5, 6, 17, and 33. Participant 11B is a contact of 
participant 11, who was found to be colonised by a shared strain. SNP=single 
nucleotide polymorphism. ST=sequence type. *Isolates that were identical, 
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21 shared an identical ST385 strain. Participant 11 was 
colonised on day 8 by an ST2067 isolate that was also 
isolated from their companion (particpant 11B, who only 
provided one sample) the following day (figure 5).
Discussion
By combining personal data of 20 European visitors to 
Laos with fine-scale genomic analyses of the strains 
isolated from their daily faecal samples, we showed 
that colonisation by an ESBL-producing Gram-negative 
bacteria during travel to endemic regions is an extremely 
dynamic process. We identified a constant influx of newly 
acquired ESBL-producing Gram-negative bacteria in all 
but one of the 20 participants. Over the duration of their 
visit, the volunteers were colonised by up to seven different 
strains, and often acquired multiple ESBL-producing 
Gram-negative bacteria species. Few studies have 
employed genome-level analyses,13 but several have 
reported isolating more than one new colonising ESBL-
producing Gram-negative bacteria strain from post-travel 
samples.7–10 Our data reveal the true scale and complexity 
at which drug-resistant bacteria colonise the intestinal 
tract in high-endemic settings; colonisation has been 
seriously underestimated, both with respect to rates of 
volunteers acquiring multidrug-resistant Gram-negative 
bacteria and number of individual strains contracted. In 
addition, our data suggest that several of our participants 
lost some of their travel-acquired ESBL-producing Gram-
negative bacteria strains while still abroad. This indicates 
that previous studies solely using before and after travel 
sampling have under-reported the extent to which 
individuals are colonised by ESBL-producing Gram-
negative bacteria. The result is especially relevant if we 
assume that multidrug-resistant Gram-negative bacteria 
simply drop below detection threshold, but do not vanish 
completely and will resurface once selection pressure 
increases again. There is a potential caveat to our study in 
that the apparent cyclic disappearance and reappearance 
of strains might be attributed to the sensitivity of the 
culture methods used, and colonising strains might have 
been missed when picking colonies for sequencing. 
Nevertheless, even this culture approach was sufficient to 
show the highly dynamic nature of the process, with 
acquisition rates far exceeding those previously reported.7–9
Our fine-scale genomic analysis enabled identification of 
a number of strains shared by the participants. Some of the 
strains colonised up to four (20%) participants, with 
between zero and five single nucleotide poly mor phisms 
between shared strains. Although direct transmission 
cannot be confirmed, the clonality of the isolates suggests 
that the two colonisation events did not result from exposure 
to a common environmental reservoir. Such reservoirs are 
generally colonised by bacteria for extended periods of time, 
which leads to extensive diversity within the bacterial 
population.21 Thus, direct transmission or acquisition 
through common exposure, such as consumption of food 
or water, appears the most likely explanation.
The population of ESBL-producing E coli isolates in 
this study has an unexpected composition. Epidem-
iological surveys of multidrug-resistant E coli, especially 
those focusing on ESBL strains, are dominated by E coli 
ST131.22 Epidemiological investigations done on E coli in 
Laos have also shown ST131 to be the dominant drug-
resistant lineage in the country.18,19 However, no ST131 
strains were isolated, and ST38 was the only lineage in 
our study that has been reported in previous investigation 
done in Laos.18.19 Examining both intestinal colonisation 
isolates19 and clinical blood stream isolates,18 they 
suggested that the ESBL-E coli population in Laos might 
be particularly dynamic and prone to frequent fluctuation. 
Of note, ST101, ST34, and ST195, and other lineages 
frequently isolated in our study have never been reported 
as clinical ESBL-producing E coli isolates in other 
countries, including the UK where high-quality longi-
tudinal data are available. Some reports describe ESBL-
producing E coli ST101,23 but none report ST34 or ST195. 
E coli ST38 has been extensively reported as an ESBL-
producing strain isolated both from humans and 
animals.24,25 Of note, the data show that most E coli strains 
were extraintestinal pathogenic (enteropathogenic E coli 
strains), indicating their potential role as pathogens.
Most previous studies of travellers have only described 
acquisition of ESBL-producing E coli. A few studies have 
reported multiple findings of ESBL-producing diarrho-
eagenic E coli17 or single findings of ESBL-producing 
Klebsiella7,10 or carbapenemase-producing E coli.8,9 Our 
data show that in addition to ESBL-producing E coli 
(219 [75%] of 292 strains) a substantial number of ESBL-
producing non-E coli Gram-negative bacteria, such as 
Citrobacter (9%), Klebsiella (5%), Acinetobacter (4%), and 
Enterobacter cloacae (4%) and even low numbers of 
Aeromonas spp and Stenotrophomonas maltophilia were 
identified. This variety in the acquired strains might be 
ascribed to the rate of exposure to various multidrug-
resistant Gram-negative bacteria because 19 participants 
attended a course of tropical medicine, which included 
daily clinical rounds at local hospitals. High multidrug-
resistant Gram-negative colonisation rates have been 
reported in visitors hospitalised in the tropics.26
The complete absence of carbapenemase-producing 
E coli in these samples is also of note. We screened for 
ESBL-producing strains, but carbapenemase producers 
would also have grown on the selective plates used. 
Additionally, whole-genome sequencing analysis showed 
a complete absence of carbapenemase genes. This 
finding was somewhat surprising in southeast Asia 
where the prevalence of carbapenem-resistant Entero-
bacteriaceae is increasing.27 Such isolates were first 
reported in Laos in 2015,5 suggesting that carbapenem 
resistance has not yet become a major problem in the 
country. Additionally, other studies have shown a low 
carriage rate of carbapenemase genes.28
Even more striking were the extremely high concen -
trations of the mobile colistin resistance gene in our 
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E coli isolates. The ST101 lineage—which dominated our 
isolate collection—has been identified as a driving 
lineage in the emergence of ESBL-producing E coli and 
mobile colistin resistance-positive E coli in the south and 
southeast Asia,29 but we observed mobile colistin 
resistance genes across a large number of lineages, 
which might be of substantial importance because 
mobile colistin resistance gene is rare in E coli linages 
surveyed to date. This confirms earlier reports showing 
that travel exacerbates the global spread of ESBL genes 
and E coli strains carrying mobile colistin resistance 
genes.30
Exposure at hospitals can be considered a limitation of 
the study because exposure to multidrug-resistant strains 
is more common in this setting. However, the main aim 
of the study was to explore the process of colonisation in a 
high-exposure setting. Although hospital visits might 
have increased the acquisition rates transient acquisition 
of multiple strains was also seen for two participants not 
visiting hospitals, and confirmed in our later studies of 
regular travellers over a 12-day trip to Benin (Kantele, 
unpublished data).
By combining real-time sampling of travellers with 
genome-level analyses, we have shown that colonisation 
by ESBL-producing Gram-negative bacteria in a high-
exposure setting is an extremely dynamic process 
characterised by competition between resistant strains 
and an individual’s own microbiota. The data suggest 
that some strains can colonise multiple participants 
potentially through direct transmission or acquisition 
from a common source. The challenge now lies in 
unravelling the mechanisms that underlie this process 
and competition between the clones, and finding tools to 
prevent colonisation already at its initial stages.
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